SAKK 16/18: Neoadjuvant Chemotherapy, Durvalumab and Immune-Modulatory RT in Stage III(N2) NSCLC. Surgical Interim Analysis
JOURNAL OF THORACIC ONCOLOGY(2023)
关键词
Surgical interim analysis,Stage III(N2),Combination treatment
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要